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Aims: To assess evolutive changes in EFA proﬁle in a cohort of CF patients and
to investigate its potential correlations with clinical and nutritional changes.
Methods: 24 patients were studied over a 8-year time span. A control group of
83 non-CF patients undergoing minor surgery was included.
Results: Mean age of study group at the onset was 7.8±3.9 years and 14±3.6
years at follow-up. 95.4% were PI. 5 had liver disease and 4 diabetes at the onset
of the study and 9 and 6 at follow-up. There was a signiﬁcant increase in BMI over
the study, 17.1±2.1 kg/m2 at the onset vs 19.4±3.1 kg/m2 at follow-up. There was
no signiﬁcant change in mean FEV1%. There was a signiﬁcant evolutive increase
in saturated, monoinsaturated EFA, DPA, MeadAcid/AA, and dihomo-g-linoleic
(DHGLA) serum levels and a signiﬁcant decrease in PUFAs, w3, w6, linoleic (LA),
lignoceric, DHA, and LAxDHA in patients as compared with controls. There was
also a signiﬁcant increase in DHGLA and decrease in LA and lignoceric serum
levels in study patients at follow-up as compared with baseline. We found some
signiﬁcant correlations between EFA proﬁle and nutritional variables. Weight at the
onset and at follow-up, and BMI at follow-up had all a negative correlation with
baseline LA serum levels. Patients with liver disease at baseline had signiﬁcantly
increased AA and at follow-up signiﬁcantly decreased w3.
Conclusions: Study group had abnormalities in EFA proﬁle at baseline, with
evolutive changes at follow-up. Signiﬁcant decrease in w6, especially LA which
correlated with nutritional impairment. DHA was decreased at baseline, and at
follow-up with no correlation with the degree of fat malabsorption.
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Background: Reducing total and saturated fat intake is recommended for the
general population. High fat intakes are still advised for those with CF but it has
been suggested that the quantity and quality of fat intake be monitored closely.
Aim: To describe changes in macronutrient and fat intake over an 8 year period.
Method: Three-day food diaries were completed by patients with CF during annual
review and nutrient composition was analysed using Compeat (Nutrition Systems,
UK). The inﬂuence of year on % energy by type (fat, CHO, protein) and % energy
by fat component (SFA, MUFA, PUFA) was examined by linear regression (SPSS
v17.0, Chicago, USA).
Results: 134 food diaries were reviewed in 28 CF subjects (10 males) age range
1 to 18 years. Over the study period % energy from fat decreased slightly and %
energy from protein increased slightly but these trends were not signiﬁcant (protein
p = 0.06, CHO p= 0.44, Fat p = 0.07). The % of energy derived from SFA, MUFA
and PUFA also remained statistically unchanged (SFA p= 0.10, MUFA p= 0.20,
PUFA p= 0.15). Saturated fat consistently contributed the most: 13−18% of total
energy (>120% of reference requirement), whilst MUFA contributed 10−13% and
PUFA 4−6% (<100% of reference requirement) of total energy respectively.
Conclusion: Macronutrients and fat source are not signiﬁcantly changing in our
population but there is an imbalance of fat-sources. With longer life expectancy
more emphasis is needed on re-distributing fat sources to avoid the potential
for hyperlipidaemia. Larger scale studies are needed to investigate fat intakes
in CF patients to guide possible new approaches and clearer advice regarding
appropriate sources of fat.
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Introduction and Aim: From the age of 10−12 yrs, a yearly oral glucose tolerance
test is advised to diagnose CF-related Diabetes (CFRD). This test does not reﬂect
a real life situation, is disliked by patients and not fully adhered to. The aim of
this study is to test the acceptance and results of a real life glucose tolerance test
(RLGTT) from Sept 2008-Dec 2009.
Materials and Methods: For the yearly check up all 27 children with CF of
12−17 yrs, not already diagnosed with CFRD (3), were admitted. The carbohydrates
of the meal are registered according to the Dutch Food Composition Table 2006.
The RLGTT consists of a 4 hour fasting period followed by eating a minimum of
1.25 g carbohydrates/kg bodyweight in a regular meal, with a maximum of 1.75 g/kg
or 75 g carbohydrates. A glucose sample was taken before and 2 hours after the
meal. A 2 hour glucose of >9mmol/L after 1.50–1.75 g/kg or >8mmol/L after
1.25–1.50 g/kg is considered abnormal. Stricter cut-off values in comparison to
OGTT were set, because the use of a meal instead of glucose.
Results: We did 33 tests in 27 patients. All patients easily accepted the test in
this design. No impaired fasting glycemia was found. In 4/33 tests (3/27 patients)
results were abnormal with a mean postprandial glucose of 11.9mmol/L (9.4 to
16.1mmol/L). 4/27 Patients had an impaired glucose tolerance (7−8.3mmol/L) but
no other symptoms. Intensive monitoring of the blood glucose followed in 3/27
patients. CFRD was subsequently diagnosed in 1 patient.
Conclusion: The RLGTT is easily accepted and implemented in regular care. An
abnormal RLGTT should be followed by intensive monitoring of blood glucose.
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Prevalence of abnormal glucose tolerance in patients with CF has been documented
to be as high as 50−75% with approximately 15% having CFRD requiring treatment
with insulin. CFRD is multifactorial and is associated with weight loss and
decreased lung function which has been shown to improve with insulin treatment.
A CFRD screening programme was introduced at our CF Centre in 2000.
The aim of this audit was to review the prevalence of CFRD in 2009 at the Prince
Charles Hospital Adult CF centre and compare to previous audits in 2005 and 2001.
A retrospective chart audit of 212 patients was completed to evaluate data including
patient demographics, documented glucose tolerance from screening, nutritional
status, CFRD treatment and CFRD complications.
As the adult CF population has increased from 2001 to 2009 two fold, the number
of patients with abnormal glucose tolerance has also increased two fold; however
the overall prevalence rate has remained stable at approximately 23−28%. When
comparing the clinical parameters of the 2009 normal and abnormal glucose toler-
ance groups, the only statistically signiﬁcant differences are seen when comparing
age and pancreatic sufﬁciency, as expected those with abnormal glucose tolerance
group are older and more likely to be pancreatic insufﬁcient. Screening for CFRD
is recommended as per the Australasian Clinical Practice Guidelines for Nutrition
in Cystic Fibrosis (2005) to identify at risk individuals, promote early intervention,
to improve health outcomes and reduce health care costs.
